drugset / Trial / NCT02932579

Utility of Pharmacogenomic Testing and Postoperative Dental Pain Outcomes

NCT02932579

Phase 4 Terminated 59 enrolled University of Rochester
RandomizedParallel-groupTriple-blindTreatment

Summary

Opioid analgesics are the most common postoperative pain medications used among dentists in the United States.Although these medications are highly effective in the postoperative dental pain management, not all patients optimally benefit from this therapy. Many suffer adverse consequences such as nausea, emesis, and psychomotor impairment, and there is a high prevalence of opioid prescription misuse among substance abusers within the dental patient population. The use of non-opioid analgesics including ibuprofen and acetaminophen in the management of postoperative dental pain has demonstrated equivalent or superior analgesic effects compared to opioid analgesic therapies, typically with significantly less adverse effects.However, despite these results, dentists have encountered a high variability in the success of non-opioid analgesic responses among the postoperative dental pain population.Thus, new strategies for earlier recognition of analgesic responses for pain medications is fundamental in the field of dentistry. Therefore, this study will evaluate the clinical utility of pharmacogenomic testing in acute postoperative dental pain management among healthy adults who undergo extraction of impacted mandibular third molar.

Timeline

Start
2017-07-01
Primary completion
2021-01-13
Completion
2021-01-13

Drugs

EvaluationDrugModalityDoseRoute
Background Acetaminophen Small molecule 325 mg
Background Acetaminophen Small molecule 650 mg
Subject Ibuprofen Small molecule 400 mg
Subject hydroxycontin Unknown 2.5 mg
Background Acetaminophen Small molecule 325 mg
Background Oxycodone Other / unclassified 5 mg

Indications

No indication recorded.